By Fineline Cube 
China-based Junion Therapeutics (Xiamen) Co., Ltd has reportedly secured RMB 100 million (USD 13.7 million) in a Series A financing round. The funding was co-led by Zhangzhou State-owned Capital Operation Group and Guoxing Investment, with additional participation from Pianzhaihuang Investment, Xiamen Strait Venture Capital, China Reform Securities Capital, and returning investor Yingke PE. The proceeds will be allocated toward regulatory filing, manufacturing, and marketing of the company’s first oral weight loss device, as well as accelerating the development of its product pipelines across multiple core innovative drug-device combination technology platforms.
Funding and Strategic Allocation
The capital raised will play a pivotal role in advancing Junion Therapeutics’ innovative oral weight loss device through the stages of regulatory approval, production, and market launch. Moreover, the funds will be instrumental in fast-tracking the development of the company’s diverse product pipelines, which leverage cutting-edge drug-device combination technologies. This strategic financial allocation underscores Junion’s commitment to innovation and its dedication to addressing unmet medical needs in the weight management space.
Investor Collaboration
The participation of a consortium of investors, including state-owned entities and private equity firms, highlights the confidence in Junion Therapeutics’ technology and market potential. Their collective investment not only provides financial backing but also brings a wealth of industry expertise and resources that will support the company’s growth and commercialization efforts.-Fineline Info & Tech